Home  /  Resource Library  /  Encouraging Response Rates and High Mobilization Success with Brentuximab Vedotin Plus GDP in Adult Relapsed/Refractory Classical Hodgkin Lymphoma: A Real-World Study

Encouraging Response Rates and High Mobilization Success with Brentuximab Vedotin Plus GDP in Adult Relapsed/Refractory Classical Hodgkin Lymphoma: A Real-World Study

Real world study of brentuximab vedotin combined with chemotherapy for treatment of relapsed Hodgkin.